ArticleScientific reports2026
FKBP10 may affect the malignant phenotype of oral squamous cell carcinoma cells through the ECM/WNT signaling pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is a common malignant tumor in the oral and maxillofacial region with a poor prognosis, and its pathophysiology has not been fully elucidated. Although FKBP10 is overexpressed in multiple malignancies, its function and regulatory mechanism in OSCC remain largely unknown. Methods: OSCC and paired adjacent normal tissue samples were collected, and public datasets including The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were integrated. Bioinformatics approaches including Weighted Gene Co-Expression Network Analysis (WGCNA), limma differential expression analysis and machine learning were applied to screen candidate target genes. Single-cell and spatial transcriptome analyses were performed to delineate the main expression domain of FKBP10 and its distribution in macrophages. Cell Counting Kit-8 (CCK-8), colony formation, Transwell, wound healing and flow cytometry assays were conducted to examine the effects of FKBP10 knockdown on the biological behaviors of SCC-9 cells. Western blot and Gene Set Enrichment Analysis (GSEA) were adopted to explore the potential molecular mechanism. Result: Bioinformatics research identified FKBP10 as a significant target gene for OSCC. FKBP10 is predominantly enriched in fibroblasts and significantly upregulated in OSCC tissues. It has a strong positive correlation with M2-type macrophage infiltration and is linked to a negative outcome for patients. FKBP10 knockdown can cause cell apoptosis, stop the cell cycle at the G0/G1 phase, and prevent SCC-9 cells from proliferating, migrating, and invading. Meanwhile, knockdown of FKBP10 downregulated the protein levels of Periostin (POSTN), Integrin Subunit Beta 5 (ITGB5) and key WNT signaling molecules. Conclusion༚FKBP10 may influence the recruitment of M2-type macrophages by regulating the ECM/integrin adhesion signal and the WNT pathway, thereby changing the tumor immune milieu and encouraging the occurrence and progression of OSCC. It is projected to become a promising biomarker and target for prognostic evaluation and targeted therapy of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.